● pepmg Research Desk · Peer-reviewed evidence review
What the research says about tesofensine
A neutral summary of the peer-reviewed literature on tesofensine, an oral triple monoamine reuptake inhibitor studied for weight reduction, whose pivotal obesity trial later drew a journal Expression of Concern. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Tesofensine is an oral triple monoamine reuptake inhibitor (it blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin); it was first tested for neurodegenerative disease, where unintended weight loss was noticed, and was then redeveloped as a candidate anti-obesity drug [1].
- In a phase 2, randomized, placebo-controlled obesity trial, tesofensine plus diet produced a mean weight loss of up to 10.6% at the highest dose versus 2.0% with diet and placebo over 24 weeks [2].
- That pivotal trial later received a journal Expression of Concern, and a separate report described under-reporting of adverse effects; tesofensine is an investigational compound and has not, in this corpus, completed and reported a large confirmatory trial [8][9].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or a recommendation to use anything. Research use only.
What tesofensine is
Tesofensine (development code NS2330) is described in the literature as a centrally acting inhibitor of the presynaptic reuptake of three monoamine neurotransmitters, noradrenaline, dopamine, and serotonin, and is thought to enhance signaling of all three [1][3]. It was originally developed for neurodegenerative conditions such as Parkinson's and Alzheimer's disease; it was ineffective for those indications, but a notable occurrence of unintended weight loss was observed, which redirected its development toward obesity [1].
The proposed mechanism for weight loss centers on appetite suppression. Preclinical work in mice and rats has reported that tesofensine acts on GABAergic neurons in the lateral hypothalamus, a feeding-related circuit, to reduce food intake [7]. Tesofensine has never been an approved medicine, and material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.
What the human research has measured
Limited evidenceThe central human study is a phase 2, randomized, double-blind, placebo-controlled trial in 203 adults with obesity across five Danish centers, in which participants received an energy-restricted diet plus tesofensine or placebo for 24 weeks. The mean weight loss with diet and placebo was 2.0%; with tesofensine plus diet it was 9.2% and 10.6% at the two higher doses, significantly greater than placebo [2]. A meta-analysis of four earlier randomized trials in Parkinson's or Alzheimer's disease (where weight was not the goal) estimated a placebo-subtracted weight loss of approximately 4% over more than 14 weeks and documented dose-dependent increases in heart rate, up to 6.8 bpm, without a consistent effect on blood pressure [5].
Mechanistic human studies examined how the weight loss arises. In a randomized appetite study, tesofensine produced a dose-dependent increase in a composite satiety score that correlated with weight loss (r = 0.36), though the satiety effect diminished as weight loss progressed [4]; a separate randomized crossover study measured 24-hour energy expenditure and appetite to probe the same question [3]. A small randomized trial (21 adults) of Tesomet, a fixed combination of tesofensine with the beta-blocker metoprolol, in hypothalamic obesity reported an additional mean weight change of -6.3% versus placebo over 24 weeks [6].
All of this is phase 2 or smaller. The trials measured percent weight change and appetite over weeks; a large phase 3 confirmatory obesity trial does not appear as a completed, reported study in this corpus.
What the studies report on safety and adverse events
Limited evidenceIn the phase 2 obesity trial the most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia [2]. Because tesofensine is a monoamine reuptake inhibitor, its cardiovascular and neuropsychiatric effects have drawn particular attention: reviews and the meta-analysis describe dose-dependent elevations in heart rate and, at the highest dose tested, increases in blood pressure [1][5]. In the small Tesomet trial, tesofensine-related events were mostly mild and included sleep disturbances (Tesomet 50%, placebo 13%), dry mouth (Tesomet 43%, placebo 0%), and headache (Tesomet 36%, placebo 0%), and one participant had a treatment-related serious adverse event of exacerbated pre-existing anxiety [6].
Two publications complicate the safety picture and must be read alongside the efficacy data. The journal that published the pivotal phase 2 obesity trial subsequently issued an Expression of Concern about that trial [8], and a separate report described under-reporting of adverse effects of tesofensine [9]. These are reasons to treat the reported adverse-event tallies as incomplete rather than settled.
None of this is a safety guarantee. The human evidence is limited and early, the pivotal trial carries an Expression of Concern, and material sold by research-chemical vendors is not manufactured to pharmacy standards or evaluated for long-term safety. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence base is characterized as limited. Human data exist and include randomized, placebo-controlled trials showing dose-related weight loss and appetite suppression over weeks [2][4][6], but the body of work is small, largely phase 2, and concentrated in a single development program. "Limited" here reflects both the early stage of the human evidence and specific integrity concerns: the pivotal obesity trial received a journal Expression of Concern [8], and adverse-event reporting was separately criticized as incomplete [9]. Much of the supporting mechanistic detail comes from animal studies [7].
Nothing here is dosing, medical, or safety guidance. Read the studies themselves, including the Expression of Concern, and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 9
- Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
- The effect of tesofensine on appetite sensations.
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.
- Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.
- Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.
- Expression of concern--Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients.
- Under-reporting of adverse effects of tesofensine.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.